UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 KLOTHO NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ACT OF 1934 For the fiscal period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 KLOTHO NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpora ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 KLOTHO NEUROSCIENCES, INC. | --- | --- | |----------------------------------------------------------------------------|--------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 ANEW MEDICAL, INC. | --- | --- | |----------------------------------------------------------------------------|---------------------- ...

Core Insights - ANEW MEDICAL, INC. has commenced trading on the NASDAQ Global Market under the ticker symbols "WENA" for common shares and "WENAW" for warrants [1][2] - The company focuses on developing novel disease-modifying therapies for neurological and age-related disorders, leveraging a management team with extensive experience in therapy development [2][3] - ANEW holds exclusive worldwide rights to develop and commercialize proprietary product platforms based on the secreted Klotho protein, which has potential applications in treating age-related diseases such as Alzheimer's and ALS [3] Company Overview - ANEW specializes in diagnostics and therapies targeting central nervous system diseases, utilizing cell and gene therapies to address conditions like Alzheimer's disease and neuromuscular diseases [3] - The company is evaluating additional core technology platforms for future development and commercialization [3] - The CEO emphasized the company's commitment to creating long-term shareholder value through strategic capital allocation and industry-specific growth strategies [5]

Company Overview - ANEW MEDICAL, INC. is a biopharmaceutical technology company focused on developing disruptive therapies for central nervous system and neurodegenerative diseases [2][6] - The company specializes in patented, novel disease-modifying technologies, including protein, gene, and cell therapies for age-related disorders such as Alzheimer's and Parkinson's Disease [6] Business Combination - ANEW MEDICAL, INC. has completed a business combination with Redwoods Acquisition Corp., resulting in the combined entity being named "ANEW MEDICAL, INC." [2][3] - The shares and warrants of the combined company are expected to begin trading on the Nasdaq Global Market under the tickers "WENA" and "WENAW" respectively [1][2] Leadership Comments - Dr. Joseph Sinkule, Founder and CEO of ANEW, expressed gratitude towards RWOD personnel and advisors for their efforts in completing the business combination and emphasized the company's access to a larger international investor pool [3] - Jiande Chen, CEO of RWOD, highlighted the potential of ANEW in developing gene therapies for neurodegenerative diseases and aging-related conditions [4] Key Technologies and Assets - ANEW holds worldwide rights to several platform technologies, including a library of melanocortin peptides and a patented medical device called Nanoject™, designed for safe and painless self-injection of various medications [6] - The company aims to announce several key milestones achieved over the past year in the development of its major platform technologies [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 Redwoods Acquisition Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or orga ...

We believe that the operational and transactional experience of our management team and their respective affiliates, and the relationships they have developed as a result of such experience, will provide us with a substantial number of potential business combination targets. These individuals and entities have developed a broad network of contacts and corporate relationships around the world. This network has grown through sourcing, acquiring and financing businesses, relationships with sellers, financing s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 (Address of principal executive offices) (Zip Code) (646) 916-5315 (Registrant's telephone number, including area code) (Former ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (646) 916-5315 (Registrant's telephone number, including area code) For the transition period from to Commission file number: 001-41340 Redwoods Acquisition Corp. (Exact name of registrant as specified ...